For those of us who don't understand: The EPM licenses for the acid form are only pieces of paper of intellectual property. They are completely useless without a pharmaceutical extractor putting them into a practical application. They then generate licensing revenues when they put those acid API's into a commercialization application by a global pharmaceutical partner by selling new drug forms of very potent cannabinoid acid based API's. The over $60 Billion Pfizer spent on Arena (cannabinoid based pipeline) and Seagen (targeting mechanism) are completely worthless without the cannabinoid acid API's provided by LABS at the Federal level be it in Canada or the U.S.
intellectual property (EPM) into practical application (LABS extraction) into commercialization (Pfizer)
That completes the business circle and that circle is not my first rodeo either.
I hope everyone understands that clearly now and what we are waiting for. All of the noise with NIH funding clinical trials in the U.S. at academic locations, institutional locations, is YEARS behind compared to the work already done in Canada.
My only question remaining now is how much of LABS does Pfizer swallow.